Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin + neomycin followed by fecal microbiota transplantation for eradication of intestinal ESBL-E/CRE carriage
2014-003727-22Phase 2Active
- Sponsor
- Hôpitaux Universitaires de Genève
- Start
- Nov 2014
- Modality
- Small Molecules, Peptides, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of colistin, neomycin, allogeneic fecal microbiota and omeprazole in Intestinal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae and gastrointestinal colonization with carbapenemase-producing Enterobacterales (2 arms), sponsored by Hôpitaux Universitaires de Genève. Started Nov 2014; status: active.
02
Drugs
colistinneomycinallogeneic fecal microbiotaomeprazole
03
Conditions
Intestinal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceaegastrointestinal colonization with carbapenemase-producing Enterobacterales
Beyond the preview
Go deeper on 2014-003727-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003727-22.